An open-label, controlled phase I pilot study to evaluate safety and immunogenicity of MVA-BN smallpox vaccine in 18-40 year old vaccinia-naive subjects with atopic disorders
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Modified vaccinia Ankara (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Bavarian Nordic
- 17 Oct 2006 Status change
- 07 Dec 2005 New trial record.